Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim
McKesson
Colorcon
Baxter
Dow

Last Updated: December 3, 2022

CLINICAL TRIALS PROFILE FOR VIDAZA


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Vidaza

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00101179 ↗ MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Completed National Cancer Institute (NCI) Phase 1 2004-11-03 MS-275 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving MS-275 together with azacitidine may kill more cancer cells. This phase I trial is studying the side effects and best dose of MS-275 when given together with azacitidine in treating patients with myelodysplastic syndromes, chronic myelomonocytic leukemia, or acute myeloid leukemia.
NCT00118287 ↗ Azacitidine and Etanercept in Treating Patients With Myelodysplastic Syndromes Completed National Cancer Institute (NCI) Phase 1/Phase 2 2005-04-01 This phase I/II trial studies how well giving azacitidine together with etanercept works in treating patients with myelodysplastic syndromes (MDS). Drugs used in chemotherapy, such as azacitidine, works in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Chemoprotective drugs, such as etanercept, may protect normal cells from the side effects of chemotherapy
NCT00118287 ↗ Azacitidine and Etanercept in Treating Patients With Myelodysplastic Syndromes Completed Fred Hutchinson Cancer Research Center Phase 1/Phase 2 2005-04-01 This phase I/II trial studies how well giving azacitidine together with etanercept works in treating patients with myelodysplastic syndromes (MDS). Drugs used in chemotherapy, such as azacitidine, works in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Chemoprotective drugs, such as etanercept, may protect normal cells from the side effects of chemotherapy
NCT00118287 ↗ Azacitidine and Etanercept in Treating Patients With Myelodysplastic Syndromes Completed Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium Phase 1/Phase 2 2005-04-01 This phase I/II trial studies how well giving azacitidine together with etanercept works in treating patients with myelodysplastic syndromes (MDS). Drugs used in chemotherapy, such as azacitidine, works in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Chemoprotective drugs, such as etanercept, may protect normal cells from the side effects of chemotherapy
NCT00313586 ↗ Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Completed National Cancer Institute (NCI) Phase 2 2006-08-01 This randomized phase II trial studies azacitidine with or without entinostat to see how well they work compared to azacitidine alone in treating patients with myelodysplastic syndromes, chronic myelomonocytic leukemia, or acute myeloid leukemia. Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Entinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving azacitidine together with entinostat may work better in treating patients with myelodysplastic syndromes, chronic myelomonocytic leukemia, or acute myeloid leukemia.
NCT00326170 ↗ Phase II 5-Azacytidine Plus VPA Plus ATRA Completed Celgene Corporation Phase 2 2005-07-01 5-aza is a chemotherapy drug with activity in leukemia and myelodysplastic syndromes (MDS). Researchers hope that valproic acid (VPA) and all-trans retinoic acid (ATRA)will increase the effects of 5-aza. The goal of this clinical research study is to find the highest safe dose of valproic acid (VPA) that can be given in combination with 5-azacytidine (5-aza) and all-trans retinoic acid (ATRA) in the treatment of AML and MDS. The safety and effectiveness of this combination therapy will also be studied. Additional blood and bone marrow samples will be requested. These samples will be used to evaluate the effect of the treatment on leukemic cells. In addition, any leftover blood and bone marrow samples that are collected at the start of the study and during the regularly scheduled evaluations to be sent for research studies. The research studies will examine changes in the blood and bone marrow cells that might help explain the causes of leukemia and MDS and how the combination of 5-aza, VPA, and ATRA works.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Vidaza

Condition Name

Condition Name for Vidaza
Intervention Trials
Acute Myeloid Leukemia 62
Myelodysplastic Syndrome 53
Leukemia 33
Myelodysplastic Syndromes 27
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Vidaza
Intervention Trials
Leukemia 135
Myelodysplastic Syndromes 132
Preleukemia 124
Leukemia, Myeloid, Acute 119
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Vidaza

Trials by Country

Trials by Country for Vidaza
Location Trials
United States 787
Canada 41
France 39
Germany 35
Australia 26
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Vidaza
Location Trials
Texas 102
California 44
New York 44
Ohio 39
Illinois 36
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Vidaza

Clinical Trial Phase

Clinical Trial Phase for Vidaza
Clinical Trial Phase Trials
Phase 4 1
Phase 3 8
Phase 2/Phase 3 2
[disabled in preview] 225
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Vidaza
Clinical Trial Phase Trials
Completed 94
Recruiting 49
Terminated 40
[disabled in preview] 51
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Vidaza

Sponsor Name

Sponsor Name for Vidaza
Sponsor Trials
National Cancer Institute (NCI) 74
M.D. Anderson Cancer Center 54
Celgene Corporation 46
[disabled in preview] 39
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Vidaza
Sponsor Trials
Other 194
Industry 185
NIH 74
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School
Dow
Colorcon
McKesson
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.